Today it was reported that a Director at BioCryst (BCRX), Stanley Erck, exercised options to buy 8,333 BCRX shares at $1.49 a share, for a total transaction value of $12.42K. The options were close to expired and Stanley Erck retained stocks.
Following this transaction Stanley Erck’s holding in the company was increased by 20.83% to a total of $434K. Following Stanley Erck’s last BCRX Buy transaction on March 16, 2009, the stock climbed by 7.7%.
See today’s analyst top recommended stocks >>
Currently, BioCryst has an average volume of 575.6K. The Company has a Price to Book ratio of 13.5088.
Starting in January 2018, BCRX received 13 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $12.00, reflecting a 34.2% upside. Four different firms, including Piper Jaffray and H.C. Wainwright, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.
